Market Report Focus On PharmaPoint: HER2-Positive Breast Cancer – China Drug Forecast and Market Analysis to 2023


“The Report PharmaPoint: HER2-Positive Breast Cancer – China Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Currently, treatment rates for HER2-positive breast cancer in China are low, with Roche reporting that approximately 30% of patients diagnosed with the disease actually received a treatment that contained an HER2-targeting therapy in 2013.

View Report At :


  • An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

  • Annualized the China HER2-Positive Breast Cancer market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.

  • Investigation of current and future market competition for HER2-Positive Breast Cancer.

  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.

  • Competitor assessment including device approval analysis and device sales forecasts.

  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.

  • Analysis of unmet needs within the market and opportunities for future players.

  • Technology trends evaluation to assess strength of pipeline.

  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.

  • Company profiles including business description, financial overview and SWOT analysis.

  • Coverage of key market players.

  • Strategic assessment of the HER2-Positive Breast Cancer sector through market impact analysis, future market scenario and company analysis.

  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the China HER2-Positive Breast Cancer market.

  • Realize device preferences of physicians who have performed the tests already.

  • Access market sizing, forecasts and quantified growth opportunities in the China HER2-Positive Breast Cancer market through 2018.

  • Quantify candidate patient populations to better design product pricing & launch plans.

  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.

  • Perform benchmarking analysis of growth opportunities against currently marketed products.

  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

  • Take a comprehensive look at the markets device pipeline and identify promising, paradigm-shifting products.

  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.

  • Whats the next big thing in the China HER2-Positive Breast Cancer market landscape? Identify, understand and capitalize.

Download Sample copy of this Report at:

Table of Contents

1 Table of Contents 6

1.1 List of Tables 9

1.2 List of Figures 12

2 Introduction 13

2.1 Catalyst 13

2.2 Related Reports 14

2.3 Upcoming Related Reports 15

3 Disease Overview 16

3.1 Etiology and Pathophysiology 16

3.1.1 Etiology 16

3.1.2 Pathophysiology 16

3.2 Basic Breast Anatomy 18

3.3 Breast Cancer Staging 19

3.4 Prognosis 20

3.5 Quality of Life 21

3.6 Symptoms 23

4 Disease Management 24

4.1 Treatment Overview 24

4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 24

4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA) 25

4.1.3 Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV) 28

4.2 China 30

4.2.1 Diagnosis 30

4.2.2 Clinical Practice 30

5 Competitive Assessment 32

5.1 Overview 32

5.2 Product Profiles – HER2-Targeted Therapies 33

5.2.1 Herceptin (trastuzumab) 33

5.2.2 Tykerb (lapatinib) 39

5.2.3 Perjeta (pertuzumab) 44

5.2.4 Kadcyla (ado-trastuzumab emtansine, T-DM1) 48

5.3 Product Profiles – General Targeted Therapies 52

5.3.1 Afinitor (everolimus) 52

5.3.2 Xeloda (capecitabine) 56

5.3.3 Avastin (bevacizumab) 59

5.3.4 Abraxane (nab-paclitaxel) 62

5.4 Hormonal Agents 64

5.4.1 Tamoxifen 65

5.4.2 Faslodex (fulvestrant) 65

5.4.3 Aromatase Inhibitors 65

6 Unmet Need and Opportunity 67

6.1 Overview 67

6.2 Brain Metastases 68

6.2.1 Unmet Need 68

6.2.2 Gap Analysis 68

6.2.3 Opportunity 70

6.3 Resistance to HER2-Targeting Therapies 70

Follow us on LinkedIn:

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074